Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180396
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bastard, Paul | - |
dc.contributor.author | Danish Blood Donor Study | - |
dc.contributor.author | Danish CHGE | - |
dc.contributor.author | Rigo Bonnin, Raúl | - |
dc.contributor.author | HGID Lab University of Hong Kong | - |
dc.contributor.author | Amsterdam UMC Covid-19 Biobank Investigators | - |
dc.contributor.author | St. James’s Hospital SARS CoV2 Interest group | - |
dc.contributor.author | Planas Obradors, Anna M. | - |
dc.contributor.author | CONSTANCES Cohort | - |
dc.contributor.author | COVID Human Genetic Effort | - |
dc.contributor.author | Solanich, Xavier | - |
dc.contributor.author | 3C-Dijon Study | - |
dc.contributor.author | Milieu Intérieur Consortium | - |
dc.contributor.author | Cerba HealthCare | - |
dc.contributor.author | Morandeira-Rego, Francisco | - |
dc.contributor.author | Etablissement du Sang study group | - |
dc.contributor.author | NIAID Immune Response To Covid Group | - |
dc.contributor.author | COVID-STORM Clinicians University of Hong Kong | - |
dc.contributor.author | NH-COVAIR Study Group | - |
dc.contributor.author | Pujol Onofre, Aurora | - |
dc.contributor.author | French COVID Cohort Study Group | - |
dc.contributor.author | CoV-Contact Cohort | - |
dc.contributor.author | Imagine COVID Group | - |
dc.contributor.author | Casasnovas Pons, Carlos | - |
dc.contributor.author | Jordan Garcia, Iolanda | - |
dc.date.accessioned | 2021-10-04T09:46:37Z | - |
dc.date.available | 2021-10-04T09:46:37Z | - |
dc.date.issued | 2021-08-19 | - |
dc.identifier.issn | 2470-9468 | - |
dc.identifier.uri | http://hdl.handle.net/2445/180396 | - |
dc.description.abstract | Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases. | - |
dc.format.extent | 26 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Association for the Advancement of Science (AAAS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1126/sciimmunol.abl4340 | - |
dc.relation.ispartof | Science Immunology, 2021, vol. 6, num. 62 | - |
dc.relation.uri | https://doi.org/10.1126/sciimmunol.abl4340 | - |
dc.rights | cc by (c) Bastard, Paul et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Immunoglobulines | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Immunoglobulins | - |
dc.title | Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 720599 | - |
dc.date.updated | 2021-10-01T11:04:40Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/948959/EU//MORE2ADA2 | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34413139 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Ciències Clíniques) Publicacions de projectes de recerca finançats per la UE Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sciimmunol.abl4340.pdf | 4.43 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License